Indena | See through Science

Peer-reviewed science on CUBO^®

The verified winning duo for gut health¹

A randomized, placebo-controlled study was conducted on 49 adults with an IBS or small bowel dysbiosis diagnosis.

All subjects followed a low-FODMAP diet; 24 of them were also supplemented with a 380-mg tablet of CUBO^®, twice a day, while the rest formed a control group and received a placebo.
After 30 days of admininistration, the study showed a significant bloating control in the supplemented group (-83%, p<0.0001), as assessed using a 4-score questionnaire (Figure 1).

Moreover, authors highlighted a relevant beneficial effect in abdominal discomfort control (Figure 2) and in intestinal dysbiosis markers (Figure 3).

Overall, the global assessment of efficacy (GAE) showed that 91.6% of supplemented subjects reported a high efficacy (Figure 4).¹

Figure 1: Graphical representation of the bloating intensity modulation in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age.

Figure 2: Graphical representation of the abdominal discomfort modulation in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age.

Figure 3: Graphical representation of urinary markers for intestinal dysbiosis in control and supplemented groups after 30 days. P<0.0001, model adjusted for sex and age. Levels of a metabolic product, resulting from bacterial action on tryptophan in the small bowel, were used as a marker of dysbiosis and malabsorption.